Prevention of REnal and Vascular ENd-stage Disease
The PREVEND Study is a prospective, observational cohort study, focussed to assess the impact of elevated urinary albumin loss in non-diabetic subjects on future cardiovascular and renal disease. PREVEND is an acronym for Prevention of REnal and Vascular ENd-stage Disease. This study started with a population survey on the prevalence of micro-albuminuria and generation of a study cohort of the general population. The goal is to monitor this cohort for the long-term development of cardiac-, renal- and peripheral vascular end-stage disease. For that purpose the participants receive questionnaires on events and are seen every three/four years for a survey on cardiac-, renal- and peripheral vascular morbidity.
Overview
- Acronym
- PREVEND
- Investigators
-
- Contacts
-
General Design
- Study design
- Cohort
- Start - End Year
- 1997 -
- Recruitment Target
-
- Individuals
- Number of Participants
- 8,592
- Number of Participants with Biological Samples
- 8,592
- Supplementary Information
-
Of the 85,421 subjects invited 40,856 responded (=48%) . We invited all consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L (n=7,768) and an a-select sample of those with an UAC <10 mg/L (n=3,395) for further studies . Of these invitees 8,592 subjects completed the first screening, that was held in 1997/1998
Access
Availability of data and biosamples
| Possible Access to Data | |
| Possible Access to Biosamples | |
| Other |
|
Marker Paper
Urinary albumin excretion is associated with renal functional abnormalities in a nondiabetic population. Pinto-Sietsma SJ, Janssen WM, Hillege HL, Navis G, De Zeeuw D, De Jong PE. J Am Soc Nephrol. 2000 Oct;11(10):1882-8
PUBMED 11004219Timeline
Population
PREVEND cohort
The Prevend cohort is enriched for the presence of an elevated urinary albumin excretion (UAE). The population is formed of Groningen inhabitants aged 28 to 75 years, who agreed to give a morning urine and to answer a short questionnaire. Of the 85,421 subjects invited to participate, 40,856 responded. The final sample is constisted of 8,592 consenting subjects with a morning urinary albumin concentration (UAC) of >10 mg/L and an a-select sample of those with an UAC <10 mg/L who completed the first screening. Pregnant women and participants with diabetes mellitus were excluded.
Selection Criteria
- Minimum age
-
18
- Maximum age
-
75
- Countries
-
- Netherlands
- Ethnic Origin
-
- Caucasian
Sources of Recruitment
- General Population
-
- Volunteer enrolment
Sample Size
- Number of Participants
- 8,592
- Number of Participants with Biological Samples
- 8,592
Data Collection Events
| # | Name | Data sources | Data sources - Biosamples | Start | End |
|---|---|---|---|---|---|
| 0 | NC1 |
|
|
1997 | 1998 |
| 1 | Second screening |
|
|
2001 | 2003 |
| 2 | Third screening |
|
|
2003 | 2006 |
| 3 | Fourth Screening |
|
|
2009 | 2012 |
Participating Studies
| Acronym | Name | Study design | Countries |
|---|
Harmonization Initiatives Included
| Acronym | Name |
|---|
Datasets
| Name | Data Collection Events | Variables |
|---|
Areas of Information Collected
- Socio-demographic and economic characteristics
- Death
- Lifestyle and behaviours
- Physical measures and assessments
- Birth, pregnancy and reproductive health history
- Laboratory measures
- Perception of health, quality of life, development and functional limitations
- Cognition, personality and psychological measures and assessments
- Diseases
- Life events, life plans, beliefs and values
- Symptoms and signs
- Preschool, school and work life
- Medication and supplements
- Social environment and relationships
- Non-pharmacological interventions
- Physical environment
- Health and community care services utilization
- Administrative information
Variables Content Summary
Areas of Information Collected
No Areas of Information Collected
No Scales Collected
Areas of Information Collected per per Population and Data Collection Event
No Areas of Information Collected
No Scales Collected
Networks
| Acronym | Name | Harmonization Initiatives | Individual Studies |
|---|
Last Update: 2023-08-10T18:19:12.099